Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) Included in the French Early Access Program for the Use of Protease Inhibitors in Genotype 1 Patients Who Failed to Eradicate HCV With a Previous Standard PEG-IFN and RBV Combination.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CUPIC
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 26 Dec 2012 Planned end date changed from 1 May 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 26 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.